FADD and rheumatoid arthritis: Together, our results provide, to our knowledge, the first evidence for the involvement of miRNA 128a in the progression of RA and suggest its potential as a unique therapeutic target for the treatment of RA by epigenetically modulating FADD expression in joint tissue and thereby the subsequent inflammatory pathways associated with RA.